

April 30, 2026



# FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the presentation of preclinical data from its CYP317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting taking place May 13-15, 2026, in Chicago, Illinois.

## **Details of the presentations are as follows:**

**Event:** Society for Investigative Dermatology 2026 Annual Meeting

**Presenter:** Chuo Fang, MD, Ph.D., Senior Scientist at FibroBiologics

**Session Date and Time:** 4:30 p.m. – 6 p.m. CT on May 15, 2026

**Location:** Salons B, C, D; Williford – 3<sup>rd</sup> Floor

For more information, please visit FibroBiologics' [website](#), email FibroBiologics at [info@fibrobiologics.com](mailto:info@fibrobiologics.com) or follow FibroBiologics on [LinkedIn](#), [YouTube](#), [Facebook](#) or [X](#).

## **About FibroBiologics**

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit [www.FibroBiologics.com](http://www.FibroBiologics.com).

## **General Inquiries:**

[info@fibrobiologics.com](mailto:info@fibrobiologics.com)

## **Investor Relations:**

Nic Johnson

Russo Partners

(212) 845-4242

[fibrobiologicsIR@russopr.com](mailto:fibrobiologicsIR@russopr.com)

## **Media Contact:**

Liz Phillips

Russo Partners  
(347) 956-7697  
[Elizabeth.phillips@russopartnersllc.com](mailto:Elizabeth.phillips@russopartnersllc.com)



Source: FibroBiologics, Inc.